Summary
The antihypertensive effect of labetalol (L) was compared with that of clonidine (C) in a randomized cross-over study in 17 hypertensive outpatients on bendrofluazide (B). After treatment for two weeks with B (5 mg qd), either L (100 mg tid) or C (0.1 mg tid) was given and their doses were titrated at 2-weekly visits until normotension was achieved, or intolerable side-effects occurred. The treatment with B and L or C was then continued in a cross-over fashion for two 6-week periods, with 3 week diuretic washouts and subsequent dose-titration periods between the treatment periods. At the end of B, the supine blood pressure (BP) was 156/101, and at the end of B + L and B + C it was 136/91 (p<0.001) and 137/91 (p<0.001), respectively, pooling the data from both periods. At the end of B, the standing BP was 155/115, and at the end of B + L and B + C 134/100 (p<0.001) and 139/106 (p<0.001), respectively. The mean daily doses required were L 476mg and C 0.335 mg. On a weight basis, labetalol had about 1/1400 of the potency of clonidine. 12 patients complained of tiredness and dry mouth on clonidine and 2 patients of unsteadiness on labetalol. Labetalol caused a psoriasiform rash on the hands in one patient and limb weakness in one patient.
Similar content being viewed by others
References
Barnett AJ, Kalowski S, Guest C (1978) Labetalol compared with prindolol plus hydrallazine in the treatment of hypertension. Med J Aust 1: 105–109
Boakes AJ, Knight EJ, Prichard BNC (1971) Preliminary studies of the pharmacological effects of 5-(1-hydroxy-2-((1-methyl-3phenylprophyl)amino)-ethyl)-salicylamide (AH 5158) in man. Clin Sci 40: 18–19
Bock KC, Heimsoth V, Merguet P, Schoenermark J (1966) Klinische und Klinisch-experimentelle Untersuchungen mit einer neuen blutdrucksenkenden Substanz: Dichlophenylaminoimidazolin. Dtsch Med Wochenschr 91: 1761–1772
Bolli P, Waal-Manning HJ, Wood AJ, Simpson FO (1976) Experience with labetalol in hypertension. Br J Clin Pharmacol 3 (Suppl): 765–771
Dargie HJ, Dollery CT, Daniel J (1976) Labetalol in resistent hypertension. Br J Clin Pharmacol 3 (Suppl): 751–755
Dollery CT (1976) Closing remarks: current status of labetalol. Br J Clin Pharmacol 3 (Suppl): 823–824
Johnson BF, Labrooy J, Munro-Faure AD (1976) Comparative antihypertensive effects of labetalol and the combination of oxprenolol and phentolamine. Br J Clin Pharmacol 3 (Suppl): 737–741
Kane J, Gregg I, Richards DA (1976) A double-blind trial of labetalol. Br J Clin Pharmacol 3 (Suppl): 737–741
Kornerup JJ, Pedersen EB, Christensen NJ, Pedersen A, Pedersen G (1979) Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension. Eur J Clin Pharmacol 16: 305–310
Lehtonen A (1979) Labetalol compared with propranolol in the treatment of hypertension: A double-blind cross-over study. Curr Ther Res 25: 378–383
Martin LE, Hopkins R, Bland R (1976) Metabolism of labetalol by animals and man. Br J Clin Pharmacol 3 (Suppl): 695–710
McNeil JJ, Louis WJ (1979) A double-blind cross-over comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension. Br J Clin Pharmacol 8: 163S-166S
Prichard BNC, Boakes AJ (1976) Labetalol in long term treatment of hypertension. Br J Clin Pharmacol 3 (suppl): 743–750
Pugsley DJ, Armstrong BK, Nassim MA, Beilin LJ (1976) Controlled comparison of labetalol and propranolol in the management of severe hypertension. Br J Clin Pharmacol 3 (suppl): 777–782
Sanders GL, Davies DM, Gales GM, Rao JG, Rawlings MD, Routledge PA (1979) A comparative study of methyldopa and labetalol in the treatment of hypertension. Br J Clin Pharmacol 8: 149S-151S
Yeh BK, Nantel A, Goldenberg LI (1971) Antihypertensive effect of clonidine. Arch Int Med 127: 233–237
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lilja, M., Jounela, A.J. & Karppanen, H. Comparison of labetalol and clonidine in hypertension. Eur J Clin Pharmacol 21, 363–367 (1982). https://doi.org/10.1007/BF00542319
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542319